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Abstract
Background: Although transition from proliferation to hypertrophic differentiation of chondrocytes is a crucial step for
endochondral ossification in physiological skeletal growth and pathological disorders like osteoarthritis, the underlying
mechanism remains an enigma. This study investigated the role of the transcription factor CCAAT/enhancer-binding protein
b (C/EBPb) in chondrocytes during endochondral ossification.
Methodology/Principal Findings: Mouse embryos with homozygous deficiency in C/EBPb (C/EBPb2/2) exhibited dwarfism
with elongated proliferative zone and delayed chondrocyte hypertrophy in the growth plate cartilage. In the cultures of
primary C/EBPb2/2 chondrocytes, cell proliferation was enhanced while hypertrophic differentiation was suppressed.
Contrarily, retroviral overexpression of C/EBPb in chondrocytes suppressed the proliferation and enhanced the hypertrophy,
suggesting the cell cycle arrest by C/EBPb. In fact, a DNA cell cycle histogram revealed that the C/EBPb overexpression
caused accumulation of cells in the G0/G1 fraction. Among cell cycle factors, microarray and real-time RT-PCR analyses have
identified the cyclin-dependent kinase inhibitor p57
Kip2 as the transcriptional target of C/EBPb. p57
Kip2 was co-localized with
C/EBPb in late proliferative and pre-hypertrophic chondrocytes of the mouse growth plate, which was decreased by the C/
EBPb deficiency. Luciferase-reporter and electrophoretic mobility shift assays identified the core responsive element of C/
EBPb in the p57
Kip2 promoter between 2150 and 2130 bp region containing a putative C/EBP motif. The knockdown of
p57
Kip2 by the siRNA inhibited the C/EBPb-induced chondrocyte hypertrophy. Finally, when we created the experimental
osteoarthritis model by inducing instability in the knee joints of adult mice of wild-type and C/EBPb+/2 littermates, the C/
EBPb insufficiency caused resistance to joint cartilage destruction.
Conclusions/Significance: C/EBPb transactivates p57
Kip2 to promote transition from proliferation to hypertrophic
differentiation of chondrocytes during endochondral ossification, suggesting that the C/EBPb-p57
Kip2 signal would be a
therapeutic target of skeletal disorders like growth retardation and osteoarthritis.
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Introduction
Most skeletal growth is achieved by endochondral ossification.
During the process, chondrocytes undergo proliferation, hyper-
trophic differentiation, and apoptosis [1], each of which is
regulated by distinct signals. Among them, chondrocyte hyper-
trophy is a rate-limiting step for the skeletal growth, being
responsible for 40–60% of the endochondral ossification [2,3].
The initiation is precisely linked with the cessation of proliferation;
however, the molecular mechanism underlying the harmonious
transition from the proliferation to hypertrophic differentiation of
chondrocytes remains an enigma.
CCAAT/enhancer-binding protein b (C/EBPb), also known as
nuclear factor-interleukin-6 (NF-IL6), is a member of the C/EBP
family of six transcription factors characterized by a carboxyl-
terminal leucine zipper dimerization domain and an adjacent
highly conserved basic DNA binding domain [4–6]. Contrary to
C/EBPa that is purely antiproliferative as a tumor suppressor in
several cell types, C/EBPb regulates expression of various genes
involved in cell differentiation, proliferation, survival, immune
function and female reproduction, as well as tumor invasiveness
and progression, through a variety of mechanisms [6].Over the
past several years, C/EBPb has been shown to control
differentiation of hematopoietic and adipogenic cells [7,8]. The
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deficient (C/EBPb2/2) mice which have been reported to
display mainly hematopoietic and adipogenic defects [9–11]. The
mice showed dwarfism with an elongated proliferative zone and
delayed chondrocyte hypertrophy in the limb cartilage, implicat-
ing the cell cycle control by C/EBPb in chondrocytes.
Cell cycle factors appear to play an important role in the control
of chondrocyte proliferation and differentiation [12,13]. During
the cell cycle activation, complexes of cyclin and cyclin-dependent
kinase (CDK) promote G1/S-phase transition from G0/G1 by
phosphorylating Rb-related pocket proteins, which activate genes
required for the S-phase entry. The cyclin-CDK complexes are
inhibited by two major families of CDK inhibitors [14]. The p16
INK4 family specifically binds and inactivates monomeric CDK4




Kip2 (p57), inhibits all G1/S-phase cyclin-CDK
complexes. Since the control of these cell cycle factors driving S-
phase onset greatly influences the commitment to cell differenti-
ation, the present study performed a screen of potential
transcriptional targets of C/EBPb using a microarray analysis,
and identified p57 as the most probable target during hypertrophic
differentiation of chondrocytes. We further investigated the
molecular mechanism underlying the regulation of skeletal growth
and endochondral ossification through the C/EBPb-p57 signal in
chondrocytes.
Results
C/EBPb2/2 mice exhibit impaired skeletal growth and
endochondral ossification
To analyze the physiological role of C/EBPb in skeletal growth
and endochondral ossification, we investigated the skeletal pheno-
types of heterozygous and homozygous C/EBPb-deficient (C/
EBPb+/2 and C/EBPb2/2) mice. Although the C/EBPb+/2
skeleton was normal, C/EBPb2/2 mice exhibited dwarfism as
compared to the wild-type littermates from embryonic stages
(Figure 1A). After birth, however, the skeletal size of C/EBPb2/2
mice gradually caught up with that of the wild type littermates
(Figure 1B), and they became similar after 1 week of age. At the
embryos, the limbs and vertebrae which are known to be primarily
formed through endochondral ossification were about 20–25%
shorter inC/EBPb2/2 mice than the wild-type, althoughcalvarial
growth, especially the width, formed through endochondral
ossification and intramembranous ossification did not show such a
difference (Figure 1D). Skeletal double staining revealed that not
only the total bone length, but also the ratio of mineralized area
shown by the positive Alizarin red staining to the total length was
decreased, confirming that endochondral ossification was impaired
by the C/EBPb deficiency (Figure 1C, E).
Hypertrophic differentiation of chondrocytes is delayed
in the C/EBPb2/2 limb cartilage
To know the mechanism underlying the impaired skeletal growth
in C/EBPb2/2 mice, we compared the tibial limb cartilage of the
wild-type and C/EBPb2/2 littermates at E16.5 (Figure 2A).
Among the resting, proliferative, hypertrophic zones, and bone
area, the proliferative zone was elongated while the hypertrophic
zone was normal in the C/EBPb2/2 limb (Figure 2B). The
number of proliferating chondrocytes with BrdU uptake was
actually increased in the C/EBPb2/2 cartilage (Figure 2C).
C/EBPb was shown by immunohistochemistry to be localized
predominantly in late proliferative and pre-hypertrophic chon-
drocytes of the wild-type cartilage, but not in the C/EBPb2/2
cartilage (Figure 2D, top). Further histological examination by
BrdU labeling, in situ hybridization of type X collagen (COL10),
immunohistochemistry of indian hedgehog (Ihh), and Alcian blue/
von Kossa double stainings supported the elongation of the
proliferative zone and delay of chondrocyte hypertrophy by the
C/EBPb deficiency (Figure 2D).
C/EBPb inhibits proliferation and promotes hypertrophic
differentiation in cultured primary chondrocytes
When primary chondrocytes derived from mouse ribs and
mouse chondrogenic cell line ATDC5 were cultured in the
differentiation medium, the C/EBPb mRNA level was increased
with the differentiation (Figure 3A), which was comparable to the
in vivo expression pattern of the limb cartilage.
We then examined the effects of loss- and gain-of-functions of
C/EBPb on proliferation and hypertrophic differentiation of the
primary rib chondrocytes. When chondrocytes from wild-type and
C/EBPb2/2 littermates were compared, cell number deter-
mined by the XTT assay was enhanced in the C/EBPb2/2
chondrocytes at 3 d of culture (Figure 3B). The percentage of
BrdU-positive cells was also increased in the C/EBPb2/2 culture
at this time point (Figure 3C), indicating that the increased cell
number was due to the enhanced proliferation, rather than the
effect on cell survival, vitality, or apoptosis. Contrarily, hypertro-
phic differentiation determined by alkaline phosphatase (ALP) and
Alizarin red stainings, and mRNA levels of COL10, matrix
metalloproteinease-13 (MMP13) and vascular endothelial growth
factor (VEGF), parameters of chondrocyte hypertrophy, were
suppressed by the deficiency (Figure 3D).
In contrast, retroviral overexpression of C/EBPb in the wild-
type rib chondrocytes suppressed the proliferation and enhanced
the hypertrophic differentiation parameters (Figure 3E, F, and G).
Collectively, C/EBPb was shown to be essential for cessation of
proliferation and promotion of hypertrophic differentiation,
suggesting arrest of the cell cycle and exit from it.
C/EBPb regulates cell cycle and p57 as the transcriptional
target
We therefore examined the regulation of cell cycle by C/EBPb.
A DNA cell cycle histogram in mouse mesenchymal C3H10T1/2
cells after the cycle synchronization revealed that the C/EBPb
overexpression enhanced accumulation of cells in the G0/G1
fraction (Figure 4A). To identify cell cycle factors lying
downstream of the C/EBPb signal, we performed a screen of
transcriptional targets of C/EBPb using a microarray analysis
(Table S1). The C/EBPb overexpression caused downregulation
of cyclin B1, B2 and D1, and upregulation of the cyclin-dependent
kinase inhibitors p16, p21 and p57, by 50% or more as compared
to the empty vector overexpression. Since the above analyses were
performed in non-chondrogenic C3H10T1/2 cells, we further
examined the expressions of the candidate genes by real-time RT-
PCR analysis in the cultures between wild-type and C/EBPb2/2
rib chondrocytes (Figure 4B). Cyclin B1, B2, and p21 were not
significantly altered by the C/EBPb deficiency, while p16 showed
contradictory upregulation. Cyclin D1 and p57 were confirmed to
be upregulated and downregulated, respectively, by the loss-of-
function of C/EBPb. However, when the expressions were further
compared between primary chondrocytes with retroviral overex-
pression of C/EBPb and the control GFP, the cyclin D1 was not
downregulated, whereas p57 was upregulated by the C/EBPb
overexpression. These indicate that p57 was the only cell cycle
factor whose expression was confirmed to be regulated positively
and negatively by the gain- and loss-of-functions of C/EBPb,
respectively. Double immunofluorescence of p57 and BrdU in the
C/EBPb in Chondrocytes
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in late proliferative and pre-hypertrophic chondrocytes which do
not exhibit BrdU uptake (Figure 4C). The p57 expression was
confirmed to be decreased in the C/EBPb2/2 cartilage.
C/EBPb transactivates p57 through direct binding to a C/
EBP motif
To know the mechanism underlying the induction of p57
expression by C/EBPb, we analyzed the promoter activity of p57
using human hepatoma HuH-7 cells and ATDC5 cells transfected
with a luciferase reporter gene construct containing the 59-flanking
sequences from 21,092 to +226 bp of the p57 promoter
(Figure 5A). The transcriptional activity determined by the
luciferase-reporter assay was enhanced by co-transfection with
C/EBPb in both cells, indicating the transcriptional induction of
p57 by C/EBPb. Deletion analysis by a series of 59-deletion
constructs identified the responsive element to C/EBPb as being
located between 2150 and 2130 bp region. The tandem-repeat
constructs of this region were confirmed to respond to the C/
EBPb overexpression depending on the repeat number in both
cells (Figure 5B). As this region contained a putative C/EBP-
binding motif [15], the site-directed mutagenesis was carried out
by creating two mutations in the motif. Both of the mutations
caused partial but significant suppression of the promoter activity
in both cells, indicating that the C/EBP motif is a responsive
Figure 1. C/EBPb2/2 mice exhibit impaired skeletal growth and endochondral ossification. (A, B) Double stainings with Alizarin red and
Alcian blue of the whole skeleton of the wild-type (WT), C/EBPb+/2, and C/EBPb2/2 littermates at E16.5 (A) and at 3 d after birth (B). Scale bar,
2 mm. (C) Double stainings of the upper limbs, hands, and lumbar spines of the two genotypes. (D) Length of humerus, ulna, femur, tibia, vertebra
(1st to 5th lumbar spines), and the calvarial length and width of the WT and C/EBPb2/2 littermates. (E) The percent ratio of Alizarin red-positive
mineralized area to total length of the long bones of the two genotypes. Data are expressed as means (bars)6SEM (error bars) of 4 bones per
genotype. *P,0.01 vs. WT.
doi:10.1371/journal.pone.0004543.g001
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nuclear extract from C/EBPb-overexpressed ATDC5 cells with
the oligonucleotide probe containing the identified responsive
element above (Figure 5D). The mutagenesis in the C/EBP motif
of the probe resulted in a failure to form the complex. Cold
competition with excess amounts of an unlabeled wild-type probe,
but not the mutated probe, suppressed the complex formation,
confirming the specific binding to the C/EBPb motif. Specificity of
C/EBPb binding was further verified by the antibody supershift.
These lines of results demonstrate that C/EBPb transactivates the
p57 promoter, at least in part, through direct binding to a C/EBP
motif between the 2150 and 2130 bp region.
The C/EBPb-p57 signal induces chondrocyte
hypertrophic differentiation
To know the functional interaction between C/EBPb and p57
during chondrocyte hypertrophic differentiation, we established
two small interfering RNA (siRNA) constructs of p57 for the gene
silencing. We initially confirmed significant decreases of p57
protein and mRNA levels by stable transfection of the two siRNAs
(Figure 5E). The C/EBPb-induced hypertrophic differentiation of
cultured rib chondrocytes determined by ALP staining and
COL10 expression was suppressed by the p57 knockdown through
the siRNA (Figure 5F), indicating the mediation of p57 in the C/
EBPb induction of hypertrophic differentiation. We confirmed
that retroviral overexpression of p57 enhanced the hypertrophy
markers in cultured ATDC5 cells (Figure 5G).
C/EBPb is involved in cartilage destruction during
osteoarthritis progression
In addition to the physiological role in skeletal growth in
embryos, we finally examined the contribution of C/EBPb in
chondrocytes under pathological conditions. We and others have
reported that endochondral ossification including chondrocyte
hypertrophy is a crucial step for cartilage destruction during
osteoarthritis progression [16–20]. We therefore created an
experimental osteoarthritis model that induces instability to the
knee joints in 8-week-old wild-type mice [17,21], and found that
C/EBPb was localized at the frontline of cartilage degradation in
the central and peripheral areas of the joint cartilage during
osteoarthritis progression (Figure 6A). To know the functional
involvement of C/EBPb under the pathological conditions, we
Figure 2. Hypertrophic differentiation of chondrocytes is delayed in the C/EBPb2/2 limb cartilage. (A) HE staining of whole tibias of
wild-type (WT) and C/EBPb2/2 littermate embryos (E16.5). Orange, red, blue, and green bars indicate layers of resting zone, proliferative zone,
hypertrophic zone, and bone area, respectively. Scale bars, 200 mm. (B) Length of proliferative and hypertrophic zones of the two genotypes. (C)
Number of BrdU-positive cells in the proximal tibia of the two genotypes. Data are expressed as means (bars)6SEM (error bars) of 5 mice per
genotype. *P,0.05 vs. WT. (D) Immunostaining with an antibody to C/EBPb (a-C/EBPb), BrdU labeling, in situ hybridization of type X collagen
(COL10), immunostaining with an antibody to Ihh (a-Ihh), and Alcian blue/von Kossa double stainings of the tibial cartilage in two genotypes. Color
bars indicate layers as above. Scale bars, 100 mm.
doi:10.1371/journal.pone.0004543.g002
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wild-type littermates that showed similar phenotypes under
physiological conditions (Figure 1A) [9]. C/EBPb2/2 mice were
not used in this experiment since their skeleton was originally
small, the joint shape was abnormal, and the activity was low, so
that mechanical stress caused by the joint instability was not
assumed to be comparable to that of wild-type mice. The cartilage
destruction as well as COL10 expression was suppressed in C/
EBPb+/2 mice, remaining a substantial undegraded matrix even
8 to 12 weeks after the surgery (Figure 6B). Quantification using
the OARSI grading system [22] confirmed significant prevention
of cartilage destruction by the C/EBPb haploinsufficiency
(Figure 6C).
Discussion
The present study for the first time demonstrated that the
transcription factor C/EBPb is essential for physiological skeletal
growth and endochondral ossification by analyses of the deficient
mice. This function was dependent on the promotion of transition
from proliferation to hypertrophic differentiation of chondrocytes
through the cell cycle control. Our further screening of cell cycle
factors identified the cyclin-dependent kinase inhibitor p57 as the
transcriptional target, and detected a responsive element of C/
EBPb in the promoter. We finally showed the functional
mediation of p57 in the C/EBPb action, and confirmed the
importance of the C/EBPb-p57 signal in the chondrocyte
hypertrophy during skeletal growth and osteoarthritis progression.
Growth retardation of C/EBPb2/2 mice was seen during
embryogenesis only and disappeared as the animals grew up after
birth under physiological conditions (Figure 1A & B). This may
possibly be due to compensatory mechanisms by other C/EBP
family members which are known to control cellular differentia-
tion in several lineages [23–26]. Regarding the mesenchymal cell
lineage, C/EBPd has been reported to show similar and
compensatory actions for adipogenic and osteogenic differentia-
tion [11,27–31]. Since the involvement of C/EBPd in chondro-
genic differentiation from the mesenchymal precursors remains
unknown, we initially examined the expression by immunohisto-
chemistry in the limb cartilage (E16.5) (Figure S1A). It was
expressed predominantly in late proliferative and pre-hypertrophic
chondrocytes, similarly to the C/EBPb expression, and this was
not altered in the C/EBPb2/2 cartilage. In addition, retroviral
overexpression of C/EBPd enhanced hypertrophic differentiation
determined by COL10 and MMP13 mRNA levels in cultured
ATDC5 cells (Figure S1B). Furthermore, the p57 promoter
activity was enhanced by the C/EBPd overexpression, although
the effect was somewhat weaker than that by C/EBPb (Figure
S1C). Although we could not detect the distinct regulation of C/
EBPb and C/EBPd expressions in the limb chondrocytes before
and after birth, their actions on chondrocyte hypertrophy might be
compensatory, especially postnatally. We are now investigating the
role of C/EBPd in the skeletal growth using the knockout mice as
well as the double knockout mice of C/EBPb and C/EBPd.
The runt family transcription factor member Runx2 [1,32,33],
parathyroid hormone/parathyroid hormone-related protein (PTH/
PTHrP)[1,34], and cyclic GMP-dependent protein kinase II (cGKII)
[35,36] are known as representative regulators of chondrocyte
hypertrophy, and interestingly, C/EBPb has been reported to be
associated with these representative regulators. C/EBPb acts as a co-
activator of Runx2 [6,37]. Generally, the complex of the members of
the C/EBP and Runx families is known to interact in the activation of
lineage-specific promoters during differentiation of osteoblasts,
adipocytes, and granulocytes [6]. Unlike Runx22/2 mice that
exhibit a complete lack of bone [32], C/EBPb2/2 mice showed
almost normal bone, raising the possibility of functional redundancy
with other isoforms such as C/EBPa or C/EBPd in osteoblast
differentiation. Contrarily, both Runx22/2 and C/EBPb2/2
mice showed impairment of chondrocyte hypertrophy during
cartilage development and growth [32,33], implicating a specific
interaction between C/EBPb and Runx2 in cartilage. In the present
study, the site-directed mutagenesis in the C/EBP motif of the p57
promoter caused significant but incomplete suppression of the
promoter activity induced by the C/EBPb overexpression
(Figure 5C). Actually, there is a putative Runx motif which lies close
to this C/EBP motif in this region. C/EBPb might therefore
stimulate the promoter activity at the Runx motif as a co-activator of
Runx2, even after the innate binding was blocked, although our
luciferase assay and EMSA so far have failed to find evidence of this.
Contrarily to Runx2, PTH/PTHrP keeps chondrocytes prolif-
erating and inhibits their hypertrophic differentiation [1,34]. The
PTH/PTHrP action via the adenyl cyclase signal in chondrocytes
is reported to be dependent on the suppression of p57 expression
[38], implicating a possible mediation of C/EBPb in this pathway.
However, our present study showed that neither PTH nor the
adenyl cyclase activator forskolin affected the C/EBPb protein
level in cultured ATDC5 cells or the activity of the p57 promoter
(2150 to +226 bp) with or without induction by C/EBPb (Figure
S2). Although C/EBPb is therefore unlikely to mediate the p57
suppression by PTH/PTHrP directly, its possible involvement as a
co-activator of Runx2 again cannot be denied here, since the
PTH/PTHrP action is also at least partly dependent on the Runx2
suppression in chondrocytes [39].
cGKII is a serine/threonine kinase lying downstream of the C-
type natriuretic peptide pathway which is essential for skeletal
growth [40]. We and others have reported that the deficiency of
cGKII in mice and rats caused dwarfism due to impaired
hypertrophic differentiation of chondrocytes [35,41], similarly to
the present C/EBPb2/2 mice. Interestingly, a previous study
showed that cGKII activated C/EBPb through phosphorylation of
glycogen synthase kinase-3b (GSK-3b) in osteosarcoma cells [42],
and our recent study showed that cGKII induced chondrocyte
hypertrophic differentiation through the GSK-3b phosphorylation
[36]. These suggest a possible mediation of the present C/EBPb-
Figure 3. C/EBPb inhibits proliferation and promotes hypertrophic differentiation in cultured primary chondrocytes. (A) Time course
of C/EBPb mRNA level determined by real-time RT-PCR analysis during differentiation of primary chondrocytes and ATDC5 cells cultured for 3 weeks
with insulin. (B) Growth curves by the XTT assay of primary chondrocytes derived from ribs of wild-type (WT) and C/EBPb2/2 littermates. (C) Ratio of
BrdU-positive cells to total cells after 3 d culture of primary chondrocytes derived from WT and C/EBPb2/2 ribs. (D) ALP and Alizarin red stainings,
and relative mRNA levels of COL10, MMP13, and VEGF of the primary chondrocytes from the two genotypes determined by real-time RT-PCR analysis
at 2 weeks of culture after confluency. (E) Growth curves of primary WT rib chondrocytes with retroviral transfection of C/EBPb (Rx-C/EBPb) or the
control GFP (Rx-GFP). (F) Ratio of BrdU-positive cells to total cells after 4 d culture of primary WT rib chondrocytes with Rx-C/EBPb or Rx-GFP. (G) ALP
and Alizarin red stainings, and relative mRNA levels of the chondrocyte hypertrophy markers of the rib chondrocytes with Rx-C/EBPb or Rx-GFP at
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nor GSK-3b overexpression altered at least the activity of the p57
promoter (2150 to +226 bp) with or without induction by C/
EBPb (Figure S3). Moreover, there is a marked difference in the
limb cartilage phenotype between cGKII2/2 and C/EBPb2/2
mice. Unlike the cGKII2/2 cartilage characterized by appear-
ance of a wide abnormal intermediate layer between the
proliferative and hypertrophic zones [35,41], the C/EBPb2/2
Figure 4. C/EBPb affects cell cycle factors. (A) Time course of DNA histograms by a flow cytometric analysis of C3H10T1/2 cells with retroviral
transfection of C/EBPb (Rx-C/EBPb) or the control GFP (Rx-GFP) after synchronization at the G2/M phase by nocodazole treatment. The horizontal and
vertical axes represent the DNA content and relative frequency, respectively. The blue and red bars indicate the rates of cells in G0/G1 and G2/M
phases, respectively. (B) Effects of loss- and gain-of-functions of C/EBPb on relative mRNA levels of cell cycle factors that were identified as possible
transcriptional targets of C/EBPb by a microarray analysis (Table S1). The levels were compared by real-time RT-PCR analysis in the cultures between
wild-type (WT) and C/EBPb2/2 rib chondrocytes (left), and between WT rib chondrocytes with Rx-C/EBPb and Rx-GFP (right). Data are expressed as
means (bars)6SEM (error bars) of 6 samples per group. (C) Double immunofluorescence of p57 (green) and BrdU (red) in the proximal cartilage of
tibias of the two genotype embryos (E16.5) and the HE staining (bottom) as a reference. Red, blue, and green bars indicate layers of proliferative zone,
hypertrophic zone, and bone area, respectively. Scale bars, 50 mm.
doi:10.1371/journal.pone.0004543.g004
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delayed chondrocyte hypertrophy (Figure 2D). Hence, the cell
cycle arrest in chondrocytes caused by C/EBPb appears to
immediately link to the start of the differentiation. The
discrepancy may be due to the diversity of signaling pathway(s)
lying downstream of cGKII and upstream of C/EBPb.W e
previously reported that cGKII phosphorylated Sox9, an inhibitor
of chondrocyte hypertrophy, and suppressed its nuclear entry [35].
Besides Sox9 and GSK-3b, vasodilator-stimulated phosphoprotein
and cysteine- and glycine-rich protein 2 are putative phosphor-
Figure 5. C/EBPb transactivates p57 through binding to a C/EBP motif and the C/EBPb-p57 signal induces chondrocyte hypertrophic
differentiation. (A) Deletion analysis using luciferase-reporter constructs containing the 59-flanking sequences from 21,092 to +226 bp of the p57
promoter and a series of deletion fragments in HuH-7 and ATDC5 cells transfected with C/EBPb or the control GFP. (B) Dose-response analysis of the
tandem repeats of the identified responsive element (2150/2130) by the luciferase-reporter assay in the HuH-7 and ATDC5 cells. (C) Site-directed
mutagenesis analysis by two mutations (mt1 and mt2) in the C/EBPb motif (2147/2141) as compared to the wild-type (WT) construct by the
luciferase-reporter assay in HuH-7 and ATDC5 cells. *P,0.01 vs. WT-C/EBPb. (D) EMSA for specific binding of the nuclear extract from C/EBPb-
transfected ATDC5 cells with the oligonucleotide probe (2160/2120) containing the WT or mt1 C/EBPb motif. The arrowhead indicates the complex.
Cold competition with 50-fold excess of unlabeled WT or mt1 probe, and supershift by an antibody to C/EBPb of the complex are also presented. (E)
The protein and mRNA levels of p57 determined by immunoblotting and real-time RT-PCR, respectively, by the p57 siRNA. Stable lines of C3H10T1/2
cells retrovirally transfected with two kinds of siRNA of p57 (Rx-si-p57-1 and Rx-si-p57-2) or the control GFP siRNA (Rx-si-GFP) were established.
*P,0.01 vs. Rx-si-GFP. (F) Effects of the p57 siRNA above on the C/EBPb-induced hypertrophic differentiation of chondrocytes. Primary rib
chondrocytes were transfected with Rx-si-p57-1, Rx-si-p57-2, or Rx-si-GFP, and further adenovirally co-transfected with C/EBPb or the control LacZ
(Ax-C/EBPb or Ax-LacZ). Hypertrophic differentiation was determined by ALP staining and relative COL10 mRNA level by real-time RT-PCR analysis at
2 weeks of culture after confluency. *P,0.01 vs. Ax-C/EBPb with Rx-si-GFP. (G) Hypertrophic differentiation of ATDC5 cells stably transfected with the
retrovirus expressing p57 (Rx-p57) or the empty vector (Rx-EV) cultured for 3 weeks with insulin and further for 2 d with inorganic phosphate.
*P,0.01 vs. Rx-EV. All graphs are expressed as means (bars)6SEM (error bars) for 6 wells/group.
doi:10.1371/journal.pone.0004543.g005
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the abovementioned GSK-3b, C/EBPb is also targeted by
multiple protein kinases including protein kinase A, calmodulin-
dependent protein kinase, Erk-1/2, ribosomal protein S6 kinase,
and CDK2 [44].
The skeletal abnormalities of C/EBPb2/2 mice were much
milder than those of the p572/2 mice which were perinatally
lethal due to various defects analogous to Beckwith-Weidemann
syndrome in children, including cleft palate and body wall
dysplasia besides severe dwarfism [38,45–47]. This may be
because p57 is more crucial for chondrocyte hypertrophic
differentiation than C/EBPb whose function could be substituted
by several upstream signals of p57. In fact, the C/EBPb deficiency
did not abrogate, but partially suppressed the p57 expression in
chondrocytes (Figure 4B, C), while the knockdown of p57 strongly
suppressed the C/EBPb-induced hypertrophic differentiation of
chondrocytes (Figure 5F). Among other cell cycle factors, mice
lacking the Rb-related pocket proteins p107 and p130 show
skeletal phenotype very similar to that of the p572/2 mice [48],
indicating that these proteins are likely to be major downstream
Figure 6. C/EBPb is involved in cartilage destruction during osteoarthritis progression. (A) Time course of joint cartilage destruction and
C/EBPb expression in the medial portion of cartilage after creating an experimental osteoarthritis model that induces instability to the knee joints of
8-week-old wild-type mice. Safranin-O staining and immunohistochemical staining with an antibody to C/EBPb (a-C/EBPb) or the non-immune
control IgG were performed at the indicated weeks after surgery. A sham operation was performed using the same approach, and assessed after
12 weeks. Boxed areas with solid and dotted lines in the top row indicate the regions of the other rows. Scale bars, 100 mm (top) and 400 mm
(others). (B) HE and Safranin-O stainings, and immunohistochemical stainings with a-C/EBPb and a-COL10 or the non-immune IgG in the tibial
cartilage of wild-type (WT) and C/EBPb+/2 littermates 8 weeks and 12 weeks after the surgery. Boxed areas in the top row indicate the regions of the
other rows. Scale bars, 200 mm (top), 400 mm (others). (C) Cartilage destruction according to the OARSI grading system. Data are expressed as means
(bars)6SEM (error bars) for 5 mice per genotype at 8 and 12 weeks. *P,0.05 vs. WT
doi:10.1371/journal.pone.0004543.g006
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chondrocytes. More interestingly, the Cip/Kip family proteins
have recently been reported to regulate pathways distinct from
that of cell cycle control [14]. Since p57 supports skeletal myoblast
differentiation by inhibiting phosphorylation of the key transcrip-
tion factor MyoD [49], this factor might also induce chondrocyte
hypertrophic differentiation by regulating crucial transcription
factors like Runx2 or Sox9. This may also explain the direct
linkage from the cell cycle arrest to cell differentiation by the C/
EBPb-p57 signaling, unlike the cGKII signal, as mentioned above.
We conclude that C/EBPb directly transactivates p57 to
promote transition from proliferation to hypertrophic differenti-
ation of chondrocytes during endochondral ossification. Besides
the anabolic function for physiological skeletal growth, the C/
EBPb haploinsufficiency in adult mice caused resistance to
cartilage destruction during osteoarthritis progression in knee
joints (Figure 6). Furthermore, C/EBPb has been reported to be
induced by proinflammatory cytokines interleukin-1 and tumor
necrosis factor-a, and to mediate the decrease of articular cartilage
matrix by suppressing the promoter activity of cartilage charac-
teristic genes like cartilage-derived retinoic acid-sensitive protein
and type II collagen [50–52]. The cytokine-induced C/EBPb also
enhances the promoter activity of prostaglandin synthetic enzymes
like cyclooxygenase-2 and phospholipase A2 [53,54] and protein-
ases like aggrecanase-1 and matrix metalloproteinase-1 [55,56] in
chondrocytes. These lines of evidence indicate that the C/EBPb-
p57 signal could be a therapeutic target of inflammatory and
degenerative joint disorders as well as skeletal growth retardation.
Materials and Methods
Ethics statement
All experiments were performed according to the protocol
approved by the Animal Care and Use Committee of the
University of Tokyo.
Animals
C/EBPb deficient mice, kindly provided by Dr. Shizuo Akira
(University of Osaka), were maintained in a C57BL/6 back-
ground. In each experiment, we compared C/EBPb2/2 or C/
EBPb+/2 mice with the wild-type littermates.
Histological analysis
The whole skeletons of WT and C/EBPb2/2 littermate
embryos (E16.5) were fixed in 99.5% ethanol, transferred to
acetone, and stained in a solution containing Alizarin red S and
Alcian blue 8GX (Sigma). For histological analysis, tibial limbs were
fixed in 4% paraformaldehyde (PFA) buffered with PBS and
sectioned in 5-mm slices. Hematoxylin-eosin (HE) stainings were
performed according to standard protocols. Alcian blue/von Kossa
double stainings were performed with 1% Alcian blue 8GX in 3%
acetate and with 5% silver nitrate. For immunohistochemistry, the
sections were incubated with antibodies to C/EBPb (C-19), p57 (C-
20), Ihh (C-15), and C/EBPd (M-17) (Santa Cruz Biotechnology
Inc.) diluted 1:500 in blocking reagent. The localization of C/EBPb
was detected with HRP-conjugated secondary antibody (Promega).
For fluorescent visualization, a secondary antibody conjugated with
Alexa Fluor 488 (Invitrogen) was used. The p57 detection was
performed using a CSA II, Biotin-Free Catalyzed Amplification
System (DAKO). In situ hybridization was performed, as we
reported previously[21].Briefly, hybridization with complementary
digoxigenin (DIG)-labeled for mouse type X collagen was
performed in a humidified chamber for 16 h at 52uC. For the
detection of DIG-labeled probes, slides were incubated with HRP-
conjugated anti-DIG rabbit polyclonal antibody (Dakopatts). The
sections were immersed in a diaminobenzidine solution to visualize
immunoreactivity. For BrdU labeling, we injected BrdU (Sigma)
intraperitoneallytopregnantmicepriortosacrifice,andthe sections
were stained using a BrdU Immunohistochemistry System (Calbio-
chem) and Alexa Fluor 568 (Molecular Probes).
Cell cultures
Primary chondrocytes were isolated from the ribs of mouse
embryos as previously described [57]. The primary chondrocytes,
HuH-7 cells and C3H10T1/2 cells were cultured in DMEM with
10% FBS. ATDC5 cells were maintained in DMEM/F12 with 5%
FBS. To induce hypertrophic differentiation, the ATDC5 cells
were cultured for 3 weeks with insulin.
Plasmids and viral vectors
C/EBPb and p57 cDNA were cloned into pMx vectors, and
retroviral vectors were generated using plat-E cells [58]. The siRNA
sequence was designed for the mouse p57 gene (NM_009876.3:
nucleotides 925–946 and 307–328) and GFP as previously
described [59] and ligated into piGENEmU6 vector (iGENE
Therapeutics). The siRNA sequence combined with the promoter
was then inserted into a retroviral pMx vector. The adenovirus C/
EBPb and LacZ expression vector were synthesized using an
Adeno-X expression system (Clontech). Two weeks after transfec-
tion, the cells were harvested and used for subsequent assays. cDNA
of cGKII and GSK-3b was ligated into pCMV-HA (Invitrogen).
Cell proliferation assay
Primary chondrocytes were inoculated at 10
3 cells per well in a
96-well plate. The proliferation of cells was examined, using an
XTT Assay Kit (Roche) at the indicated time point. The
absorbance of the product was quantified using a MTP-300
microplate reader (Corona Electric). For BrdU detection analysis,
we labeled the chondrocytes with 10 mM BrdU (Sigma) for 18 h
and the cells were stained using a BrdU Immunohistochemistry
System (Calbiochem).
Chondrocyte differentiation assay
Primary chondrocytes were cultured for two weeks after
confluency, and the total RNA was extracted to assess the COL10,
MMP13, and VEGF mRNA levels. For the ALP staining, cells were
stained with a solution containing 0.01% Naphthol AS-MX
phosphate disodium salt (Sigma), 1% N, N-dimethyl-formamide
(Wako), and 0.06% fast blue BB (Sigma). For the Alizarin red S
staining, cells were stained with 2% Alizarin red S solution (Sigma).
Flow cytometric analysis
C3H10T1/2 cells with retroviral transfection with C/EBPb or
GFP were incubated for 18 h in the presence of 0.2 mM
nocodazole for synchronization at the G2/M phase. Then, cells
were suspended in citrate buffer and stained with propidium
iodide. DNA content was analyzed with EPICS XL and XL
EXPO32 instruments (Beckman).
Real-time RT-PCR
The total RNA was extracted using an ISOGEN Kit (Wako)
and an RNeasy Mini Kit (QIAGEN). One mg of RNA was reverse-
transcribed with a Takara RNA PCR Kit (AMV) ver.2.1 (Takara)
to generate single-stranded cDNA. PCR was performed with an
ABI Prism 7000 Sequence Detection System (Applied Biosystems).
All reactions were run in triplicate. Primer sequence information is
available upon request.
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The human p57 promoter regions were cloned into the pGL4.10
vector (Promega). Other deletion constructs were created by the
PCR technique. Tandem-repeat constructs were created by ligating
the double strand oligonucleotides from 2150 to 2130 bp into
pGL4.10 vector. Transfection in HuH-7 and ATDC5 cells was
performed in quadruplicate using Fugene (Roche). For PTH or
forskolin stimulation, cells were cultured with PTH (10 nM) or
forskolin (10 nM) at the time of transfection. The luciferase assay
was performed with a PicaGene Dual SeaPansy Luminescence Kit
(Toyo Ink) and GloMax
TM 96 Microplate Luminometer (Promega).
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts were prepared from ATDC5 cells adenovirally
transfected with C/EBPb. Oligonucleotide probes of the 2160 to
2120 bp region sequence in the p57 promoter were labeled with
digoxigenin by using a DIG gel shift kit (Roche). For competition
analyses, 50-fold excess of unlabeled competitor probe was included
in the binding reaction. For the supershift experiments, 1 mLo fa n
antibody to C/EBPb (Santa Cruz Biotechnology Inc.) was added.
Microarray analysis
Total RNA was isolated from C3H10T1/2 cells with retroviral
introduction of C/EBPb or the empty vector after 1 week of
culture. The microarray experiment was performed using the
Gene Chip Mouse Genome 430 2.0 Array (Affymetrix), scanned
by GeneChip Scanner 3000, and analyzed using GCOS ver 1.4
software.
Immunoblotting
ATDC5 cells were cultured with PTH (10 nM) or forskolin (10
nM) for 0 to 30 min, and then their cytoplasmic and nuclear
proteins were extracted with an NE-PER (Pierce Chemical). For
immunoblot analysis, lysates were fractionated by SDS-PAGE and
transferred onto nitrocellulose membranes (BIO-RAD). The
membranes were incubated with an antibody to C/EBPb (Santa
Cruz), or an antibody to actin (Sigma). Immunoreactive bands
were visualized with ECL Plus (Amersham Biosciences).
Osteoarthritis experiment
The surgical procedure to create an osteoarthritis experimental
model was performed on 8-week-old male mice, as we have
reported previously [17,20,21]. At the indicated time points after
surgery, the mice were killed, and the entire knee joints were
dissected and fixed for 24 h at 4uC in 4% PFA. The specimens
were decalcified for 2 weeks with 10% EDTA (pH 7.4) at 4uC and
sectioned in 5-mm slices. Sections were stained with Safranin O–
fast green. Destruction of cartilage was quantified according to the
OARSI grading system [22]. For immunohistochemistry, the
sections were incubated with antibodies to C/EBPb (Santa Cruz),
COL10 (LSL) or the nonimmune rabbit IgG as the negative
control diluted 1:500 in blocking reagent, and the localization was
detected with HRP-conjugated secondary antibody (Promega).
Statistical analysis
Means of groups were compared by ANOVA, and significance
of differences was determined by post-hoc testing using Bonferro-
ni’s method.
Supporting Information
Table S1 Microarray analysis shows the changes in expression of
cell cycle factors by C/EBPb overexpression. Ratios of mRNA
levels in C3H10T1/2 cells with retroviral introduction of C/EBPb
in comparison with the control empty vector were determined by
Gene Chip Mouse Genome 430 2.0 Array (Affymetrix). All results
of the microarray analysis are provided at ArrayExpress (accession
number: E-MEXP-1984).
Found at: doi:10.1371/journal.pone.0004543.s001 (0.02 MB
PDF)
Figure S1 C/EBPd shows similar expression and function in
chondrocytes to those of C/EBPb. (A) Immunostaining with an
antibody to C/EBPd in the tibial cartilage of wild-type (WT) and
C/EBPb2/2 littermates (E16.5). Red, blue, and green bars
indicate layers of proliferative zone, hypertrophic zone, and bone
area, respectively. Scale bars, 100 mm. (B) Relative mRNA levels
of COL10, MMP13, and VEGF of ATDC5 cells with retroviral
transfection of C/EBPd or the control GFP determined by real-
time RT-PCR at 2 weeks of culture after confluency. (C) The p57
promoter activity in ATDC5 cells transfected with luciferase-
reporter construct containing the 59-flanking sequences from
2150 to +226 bp of the p57 promoter with effector plasmid
expressing C/EBPd, C/EBPb, or the control GFP. All data are
expressed as means (symbols or bars)6SEM (error bars) of 6 wells
per group. *P,0.01 vs. GFP.
Found at: doi:10.1371/journal.pone.0004543.s002 (0.68 MB
PDF)
Figure S2 PTH and forskolin have no effects on C/EBPb
protein level and p57 promoter activity. (A) Time course of C/
EBPb protein level in cultured ATDC5 cells. After the indicated
time of treatment with PTH (10 nM) and forskolin (10 nM), the
C/EBPb protein levels in the cytoplasmic fraction (C) and nuclear
fraction (N) were determined by immunoblotting with an antibody
to C/EBPb or actin as the loading control. (B) Effects of PTH,
forskolin or the control on HuH-7 cells transfected with luciferase-
reporter construct containing the 59-flanking fragment (2150 to
+226 bp) of the p57 promoter with effector plasmid expressing C/
EBPb or GFP as the control. The promoter activity was
determined by the luciferase assay after 2 d of treatment.
Found at: doi:10.1371/journal.pone.0004543.s003 (0.07 MB
PDF)
Figure S3 Effects of cGKII and GSK-3b overexpression on p57
promoter activity. The promoter activity was determined by the
luciferase assay in HuH-7 cells transfected with luciferase-reporter
construct containing the 59-flanking fragment (2150 to +226 bp)
of the p57 promoter with effector plasmid expressing C/EBPb or
GFP as the control.
Found at: doi:10.1371/journal.pone.0004543.s004 (0.02 MB
PDF)
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